Tharimmune (THAR) Competitors $1.75 -0.01 (-0.57%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. BIVI, RVPH, CING, JATT, MTEX, QTTB, MRKR, LPCN, CARM, and PRPHShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include BioVie (BIVI), Reviva Pharmaceuticals (RVPH), Cingulate (CING), JATT Acquisition (JATT), Mannatech (MTEX), Q32 Bio (QTTB), Marker Therapeutics (MRKR), Lipocine (LPCN), Carisma Therapeutics (CARM), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors BioVie Reviva Pharmaceuticals Cingulate JATT Acquisition Mannatech Q32 Bio Marker Therapeutics Lipocine Carisma Therapeutics ProPhase Labs Tharimmune (NASDAQ:THAR) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Which has better valuation & earnings, THAR or BIVI? BioVie is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$12.20M-$7.88-0.22BioVieN/AN/A-$32.12M-$7.91-1.03 Do analysts rate THAR or BIVI? Tharimmune currently has a consensus target price of $17.00, suggesting a potential upside of 871.43%. Given Tharimmune's higher possible upside, equities analysts plainly believe Tharimmune is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is THAR or BIVI more profitable? BioVie's return on equity of -100.88% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -489.33% -264.34% BioVie N/A -100.88%-78.49% Do institutionals & insiders hold more shares of THAR or BIVI? 1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 10.0% of Tharimmune shares are owned by insiders. Comparatively, 2.4% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to THAR or BIVI? In the previous week, BioVie had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.30 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the news media. Company Overall Sentiment Tharimmune Neutral BioVie Neutral Which has more risk & volatility, THAR or BIVI? Tharimmune has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. SummaryBioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.66M$2.92B$5.54B$9.00BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-0.2221.0327.1820.18Price / SalesN/A293.12431.49125.05Price / CashN/A41.1936.8257.86Price / Book2.577.758.085.59Net Income-$12.20M-$54.95M$3.17B$248.60M7 Day Performance-3.85%5.68%4.13%5.18%1 Month Performance9.37%5.09%3.80%7.11%1 Year Performance-50.14%7.54%34.35%21.73% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.7768 of 5 stars$1.75-0.6%$17.00+871.4%-48.8%$4.66MN/A-0.222BIVIBioVie0.6359 of 5 stars$0.99+5.8%N/A+111.8%$18.29MN/A-0.1210News CoverageRVPHReviva Pharmaceuticals2.2782 of 5 stars$0.38+2.9%$9.00+2,268.4%-69.4%$18.24MN/A-0.485CINGCingulate2.7212 of 5 stars$4.27+3.1%$26.00+508.9%+1,135.6%$18.15MN/A-0.5020News CoverageJATTJATT AcquisitionN/A$1.05flatN/A-67.7%$18.11MN/A0.003High Trading VolumeMTEXMannatech0.2811 of 5 stars$9.45+2.9%N/A+17.5%$17.96M$117.87M-94.50250Gap UpQTTBQ32 Bio2.0313 of 5 stars$1.46+1.7%$12.17+731.1%-92.7%$17.81M$1.16M-0.3039MRKRMarker Therapeutics3.9099 of 5 stars$1.57+4.0%$13.17+738.6%-65.6%$17.76M$6.59M-1.1860Positive NewsLPCNLipocine1.577 of 5 stars$3.21+0.5%$9.00+180.8%-57.8%$17.15M$11.20M-3.1410CARMCarisma Therapeutics2.3847 of 5 stars$0.41+0.5%$1.93+373.0%-66.2%$17.05M$19.63M-0.2620Gap DownPRPHProPhase Labs0.7823 of 5 stars$0.40+5.0%N/A-87.1%$16.66M$6.77M-0.32130 Related Companies and Tools Related Companies BioVie Competitors Reviva Pharmaceuticals Competitors Cingulate Competitors JATT Acquisition Competitors Mannatech Competitors Q32 Bio Competitors Marker Therapeutics Competitors Lipocine Competitors Carisma Therapeutics Competitors ProPhase Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
